Last reviewed · How we verify
NCT04294511
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma
Phase 2 trial testing Camrelizumab in Combination With Neoadjuvant Chemotherapy in Osteosarcoma in 75 participants. Status unknown.
16 March 2021
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 26 December 2019 |
| Primary completion | 16 March 2021 |
| Estimated completion | 16 September 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Camrelizumab in Combination With Neoadjuvant Chemotherapy — full drug profile →
Conditions studied
- Osteosarcoma — all drugs for Osteosarcoma →
Sponsor
Sun Yat-sen University
Who can join
Adults 14 to 65, any sex, with Osteosarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
Liu ZL, Chen HH, Zheng LL, Sun LP, et al · · 2023 · cited 808× · PMID 37169756 · DOI 10.1038/s41392-023-01460-1 -
Advances on immunotherapy for osteosarcoma.
Yu S, Yao X. · · 2024 · cited 146× · PMID 39245737 · DOI 10.1186/s12943-024-02105-9 -
Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.
Rathore R, Van Tine BA. · · 2021 · cited 81× · PMID 33809018 · DOI 10.3390/jcm10061182 -
Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future.
Zhang Z, Tan X, Jiang Z, Wang H, et al · · 2022 · cited 37× · PMID 36324681 · DOI 10.3389/fphar.2022.1031527 -
Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.
Nirala BK, Yamamichi T, Petrescu DI, Shafin TN, et al · · 2023 · cited 36× · PMID 37894474 · DOI 10.3390/cancers15205108 -
Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK, Yamamichi T, Yustein JT. · · 2023 · cited 32× · PMID 37511127 · DOI 10.3390/ijms241411367 -
Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?
Yiong CS, Lin TP, Lim VY, Toh TB, et al · · 2023 · cited 26× · PMID 37612756 · DOI 10.1186/s40364-023-00513-5 -
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma.
Park JA, Cheung NV. · · 2023 · cited 26× · PMID 37569894 · DOI 10.3390/ijms241512520
Verify or expand the search:
- PubMed search for NCT04294511
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Camrelizumab in Combination With Neoadjuvant Chemotherapy
Trials testing the same drug.
- NCT04606108 — Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma · Phase 2 · unknown
Other recruiting trials for Osteosarcoma
Currently open trials in the same condition.
- NCT07479732 — Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma · Phase 1, PHASE2 · recruiting
- NCT06935409 — Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-li · Phase 3 · active not recruiting
- NCT06521567 — A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer · Phase 1, PHASE2 · active not recruiting
- NCT06709495 — Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol · Phase 1, PHASE2 · recruiting
- NCT06541262 — Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04294511 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 4 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04294511.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing